Vaccine clinical trials with dynamic borrowing of historical controls: Two retrospective studies

被引:3
|
作者
Callegaro, Andrea [1 ]
Karkada, Naveen [1 ]
Aris, Emmanuel [1 ]
Zahaf, Toufik [1 ]
机构
[1] GSK, Dept Biostat, Rue Inst 89, B-1330 Rixensart, Belgium
关键词
adaptive design; Bayesian inference; clinical trials; dynamic borrowing; historical controls; vaccine efficacy; vaccine trials; (HPV)-16/18 AS04-ADJUVANTED VACCINE; CONFIDENCE-INTERVALS; POWER PRIOR; IMMUNOGENICITY; INFECTION; EFFICACY; SAFETY; PRIORS; RATIO;
D O I
10.1002/pst.2283
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Traditional vaccine efficacy trials usually use fixed designs with fairly large sample sizes. Recruiting a large number of subjects requires longer time and higher costs. Furthermore, vaccine developers are more than ever facing the need to accelerate vaccine development to fulfill the public's medical needs. A possible approach to accelerate development is to use the method of dynamic borrowing of historical controls in clinical trials. In this paper, we evaluate the feasibility and the performance of this approach in vaccine development by retrospectively analyzing two real vaccine studies: a relatively small immunological trial (typical early phase study) and a large vaccine efficacy trial (typical Phase 3 study) assessing prophylactic human papillomavirus vaccine. Results are promising, particularly for early development immunological studies, where the adaptive design is feasible, and control of type I error is less relevant.
引用
收藏
页码:475 / 491
页数:17
相关论文
共 48 条
  • [41] Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
    Gaudinski, Martin R.
    Houser, Katherine V.
    Morabito, Kaitlyn M.
    Hu, Zonghui
    Yamshchikov, Galina
    Rothwell, Ro Shauna
    Berkowitz, Nina
    Mendoza, Floreliz
    Saunders, Jamie G.
    Novik, Laura
    Hendel, Cynthia S.
    Holman, LaSonji A.
    Gordon, Ingelise J.
    Cox, Josephine H.
    Edupuganti, Srilatha
    McArthur, Monica A.
    Rouphael, Nadine G.
    Lyke, Kirsten E.
    Cummings, Ginny E.
    Sitar, Sandra
    Bailer, Robert T.
    Foreman, Bryant M.
    Burgomaster, Katherine
    Pelc, Rebecca S.
    Gordon, David N.
    DeMaso, Christina R.
    Dowd, Kimberly A.
    Laurencot, Carolyn
    Schwartz, Richard M.
    Mascola, John R.
    Graham, Barney S.
    Pierson, Theodore C.
    Ledgerwood, Julie E.
    Chen, Grace L.
    LANCET, 2018, 391 (10120) : 552 - 562
  • [42] Modified Simon's Two-Stage Design for Phase IIA Clinical Trials in Oncology-Dynamic Monitoring and More Flexibility
    Shih, Weichung Joe
    Zhao, Yunqi
    Xie, Tai
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2023, 15 (04): : 838 - 844
  • [43] Time arrow in published clinical studies/trials indexed in MEDLINE: a systematic analysis of retrospective vs. prospective study design, from 1960 to 2017
    Ciulla, Michele M.
    Vivona, Patrizia
    PEERJ, 2019, 7
  • [44] Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory
    McLean, Chelsea
    Barry, Houreratou
    Kieh, Mark
    Anywaine, Zacchaeus
    Rogers, Baimba Tapima
    Doumbia, Seydou
    Sirima, Sodiomon B.
    Serry-Bangura, Alimamy
    Beavogui, Abdoul Habib
    Gaddah, Auguste
    Katwere, Michael
    Hendriks, Jenny
    Keshinro, Babajide
    Eholie, Serge
    Kibuuka, Hannah
    Kennedy, Stephen B.
    Anzala, Omu
    Samai, Mohamed
    D'Ortenzio, Eric
    Leigh, Bailah
    Sow, Samba
    Thiebaut, Rodolphe
    Greenwood, Brian
    Watson-Jones, Deborah
    Douoguih, Macaya
    Luhn, Kerstin
    Robinson, Cynthia
    EBIOMEDICINE, 2023, 91
  • [45] The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials
    Essink, Brandon
    Chu, Laurence
    Seger, William
    Barranco, Elizabeth
    Le Cam, Nancy
    Bennett, Hamilton
    Faughnan, Veronica
    Pajon, Rolando
    Paila, Yamuna
    Bollman, Brooke
    Wang, Steven
    Dooley, Jacqueline
    Kalidindi, Shiva
    Leav, Brett
    LANCET INFECTIOUS DISEASES, 2023, 23 (05) : 621 - 633
  • [46] Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials
    Chen, Gui-Ling
    Qiu, Yuan-Zheng
    Wu, Kai-Qi
    Wu, Ying
    Wang, Yuan-Hui
    Zou, Yu-Ying
    Peng, Cong-Gao
    Zhao, Jie
    Su, Chang
    Ma, Jun-Heng
    Ni, Shao-Nan
    Wang, Xing
    Jin, Ting-Han
    Jiang, Qi
    Guo, Tong
    Xu, Yan
    Huang, Chao-Chao
    Zhang, Qing
    Liu, Kai-Li
    Ji, Li
    Yang, Han-Yu
    Li, Chun-Lei
    Su, Yu-Wen
    Lu, Xiang
    Li, Lan-Juan
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (03)
  • [47] Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adults
    Pillet, Stephane
    Couillard, Julie
    Trepanier, Sonia
    Poulin, Jean-Francois
    Yassine-Diab, Bader
    Guy, Bruno
    Ward, Brian J.
    Landry, Nathalie
    PLOS ONE, 2019, 14 (06):
  • [48] Adherence to a flexible extended regimen for oral hormonal contraception provided in blister packaging compared with an adherence-supporting digital tablet dispenser: historical comparison of data from two clinical studies
    Elliesen, Joerg
    Trummer, Dietmar
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2016, 8 : 351 - 356